Tomas J. Heyman

Executive

Director

Akero Therapeutics, Inc.Exelixis, Inc.Legend Biotech Corp

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 1 saleJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€178k

Latest filing published 28 Sept 2026 for Legend Biotech Corp. Read the official filing

Filing timeline

BuySale

Tomas J. Heyman

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

Tomas J. Heyman: trading record in brief

Tomas J. Heyman, listed as senior executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Exelixis, Inc., Akero Therapeutics, Inc. and Legend Biotech Corp. Over a trading history stretching from 31 May 2023 to 24 September 2026, the count stands at 9 filings.

On the market, this insider has only sold: 1 sale, €178k in total. Besides market trades, the filings include 6 share grants and 1 option exercise.

Most recently, on 28 September 2026, the filings show a share grant in Legend Biotech Corp. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.